Editor: Leisheng Zhang

Stem Cells in Clinical Application and Productization

eBook: US $39 Special Offer (PDF + Printed Copy): US $72
Printed Copy: US $52
Library License: US $156
ISBN: 978-981-5196-63-4 (Print)
ISBN: 978-981-5196-62-7 (Online)
Year of Publication: 2024
DOI: 10.2174/97898151966271240101

Introduction

Stem cells with self-renewal and multi-lineage differentiation potential have potential for developing medicines for a range of refractory and recurrent disease. This book mainly focuses on the landscape of the biological properties and translational research of stem cells types, including hematopoietic stem cells (HSCs), neural stem cells (NSCs) and mesenchymal stem/stromal cells (MSCs).

The book also introduces readers to the current updates and development prospects of stem cells in singular or combination therapies with advanced biomaterials and technological innovations towards large-scale standardization and productization.

Key Features:

  • - Introduces readers to stem cell biology and tissue engineering
  • - Covers innovations in stem cell therapy and biomaterials
  • - Includes a brief guide to commercialization of stem cell technology
  • - Includes references for advanced readers

The contents will strengthen the reader’s understanding of stem cell-based therapies. This book is a primer on stem cell and regenerative medicine for a wide readership including students, healthcare professionals, researchers and general readers.

Readership

Students, healthcare professionals, researchers and general readers.

Foreword

Stem cells possess self-renewal and multi-lineage differentiation potential, which are capable of differentiating into more than 200 types of functional cells in vitro and thus hold promising applications in regenerative medicine. Generally, stem cells can be divided into four types totipotent stem cells ( e.g., zygotes), pluripotent stem cells ( e.g., embryonic stem cells, induced pluripotent stem cells), multipotent stem cells ( e.g., mesenchymal stem/stromal cells, neural stem cells), and unipotent stem cells ( e.g., amniotic epithelial stem cells, hematopoietic stem cells).

State-of-the-art renewal has indicated the combination of biomaterials ( e.g., hydrogels, hydroxyapatites, nano-materials, scaffolds) with mesenchymal stem/stromal cells (MSCs), which are heterogeneous populations with unique hematopoietic-supporting and immunoregulatory properties for tissue engineering purposes. For decades, we and other investigators have demonstrated the promising prospects of MSC-based tissue engineering in regenerative medicine, and in particular, for the administration of recurrent and refractory disease. Very recently, a number of talented experts took advantage of the biomaterial/MSC composite or scaffolds for applications in osteoarthritis, burn wounds, and refractory wounds associated with diabetic foot as well. Strikingly, the composite or scaffold showed superiority in the continuous improvement of the biological functions of the injured areas over biomaterials or MSCs, respectively. Therewith, stem cells, and biomaterials are recognized as “seeds” and “soils”, which are of equal importance for tissue engineering. Collectively, stem cell and biomaterial-based tissue engineering is a core frontier area for disease remodeling and the accompanied regenerative medicine in the future.

Therewith, in this book, Professor Leisheng Zhang in our team and the coauthors have summarized the latest updates of biomaterial/stem cell composites in tissue engineering and put forward the hotspot issues in the future including 3D printing, biomaterial/MSC-exosomes in preclinical and clinical applications.

Zhongchao Han
National Engineering Research Center for Cell Products
Jiangxi Research Center of Stem Cell Engineering
Jiangxi Health-Biotech Stem Cell Technology Co., Ltd
Shangrao, Jiangxi Province, 334000, China